Quick Answer
Tyra Biosciences, Inc. reported Total Assets of $282.61 million for the year ending 2025.
- Tyra Biosciences, Inc. showed a decrease of -22.3% in Total Assets from 2024 to 2025.
- This data is from Tyra Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $315.97 million | Q1 2022: $298.97 million | Q2 2022: $287.12 million | Q3 2022: $275.99 million | Q1 2023: $255.06 million | Q2 2023: $250.01 million | Q3 2023: $238.36 million | Q1 2024: $404.74 million | Q2 2024: $392.46 million | Q3 2024: $380.59 million | Q1 2025: $343.48 million | Q2 2025: $321.50 million | Q3 2025: $301.85 million.
- Over the full 6 years of available data (2020 to 2025), Tyra Biosciences, Inc.'s Total Assets has grown by 1,665.1%.
- Historical annual values: Fiscal year 2025: $282.61 million | Fiscal year 2024: $363.56 million | Fiscal year 2023: $225.86 million | Fiscal year 2022: $266.18 million | Fiscal year 2021: $306.70 million | Fiscal year 2020: $16.01 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: